🇺🇸 FDA
Pipeline program

HYQVIA

161503

Approved mab completed

Quick answer

HYQVIA for Primary Immunodeficiency Diseases (PID) is a Approved program (mab) at Takeda with 2 ClinicalTrials.gov record(s).

Program details

Company
Takeda
Indication
Primary Immunodeficiency Diseases (PID)
Phase
Approved
Modality
mab
Status
completed

Clinical trials